Obesity Pillars roundtable: Excessive weight reduction with highly effective anti-obesity medications (heAOMs)

The Historic perspective section (page unavailable) associates semaglutide’s approval with mean weight reductions often reaching 15–20%. It does not give the STEP-1 result of −14.9%, the placebo result of −2.4%, the 2.4 mg weekly dose, or the 68-week endpoint; searches for those details found no matching passage. (LLM, conf=0.83)

The section “Approach to the patient with obesity experiencing substantial weight reduction with heAOMs” (page unavailable) describes nausea and vomiting as side effects in one patient taking a highly effective anti-obesity medication. It does not identify that medication as semaglutide or tirzepatide, establish which adverse events are most common, or describe diarrhea and constipation as treatment-related events; its table lists chronic diarrhea as a possible cause of weight loss instead. (LLM, conf=0.84)

The section “Approach to the patient with obesity experiencing substantial weight reduction with heAOMs” describes a patient whose nausea and vomiting were side effects of heAOM therapy. It does not establish an increased risk for GLP-1–activating AOMs as a group or link diarrhea, dyspepsia, and constipation to those drugs; its table lists chronic diarrhea as a possible cause of weight loss, not a drug adverse event. No page number is available in our copy. (LLM, conf=0.83)

The section on managing substantial weight reduction with heAOMs discusses patients whose weight loss may be excessive, supporting that it can occur during treatment. The passages do not establish how often it occurs, so the qualifier “rare” is not supported. (LLM, conf=0.82)

The Historic perspective section discusses semaglutide for weight reduction and mentions potential cardiovascular benefits, but does not report changes in waist circumference or systolic blood pressure. Searches for those measures and for patient-reported physical function found no passage in our copy addressing the claimed outcomes; page numbers were not available. (LLM, conf=0.73)

The supplied passage on excessive weight reduction does not report STEP-1 outcomes. The References section lists a semaglutide trial, but searches of our copy for 50.5%, ≥15% weight loss, and 68 weeks found no passage reporting the claimed result. (LLM, conf=0.70)

The section “Approach to the patient with obesity experiencing substantial weight reduction with heAOMs” describes an individual case of nausea and vomiting, but gives no registration-trial findings on event severity, duration, or treatment discontinuation. Searches for mild or moderate gastrointestinal events, transient effects, and discontinuation found no passage addressing those claims; page numbers were unavailable in our copy. (LLM, conf=0.76)

The section 'Approach to the patient with obesity experiencing substantial weight reduction with heAOMs' describes one patient’s nausea and vomiting during heAOM therapy, but does not characterize most gastrointestinal adverse events as mild or moderate, dose-dependent, or transient. A search for those terms found no passage establishing that pattern; the paper’s reference to dose dependence concerns weight reduction, not adverse events. Page numbers were unavailable in our copy. (LLM, conf=0.72)